Investing
Cathie Wood's ARK Invest Sells Over 350,000 Shares of Takeda Pharma
Published:
Last Updated:
One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 350,000 shares of Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) on Wednesday, as the share price of this fund traded relatively flat in the day’s session. Its share price has greatly improved over the past year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) sold 366,228 shares of Takeda. At Wednesday’s closing price, this would have valued this sale at roughly $6.2 million. This is only a small fraction of the total holdings. This fund is up 84% over the past 52 weeks.
Here is a quick look at all the other sales that took place across all ARK ETFs:
| Fund | Ticker | Company | Shares |
|---|---|---|---|
| ARKF | TCSLI | TCS GROUP HOLDING PLC | 35,354 |
| ARKG | NVS | NOVARTIS AG | 128,903 |
| ARKG | PSTI | PLURISTEM THERAPEUTICS INC | 1,357 |
| ARKG | SRPT | SAREPTA THERAPEUTICS INC | 22,178 |
| ARKG | TAK | TAKEDA PHARMACEUTICAL CO LTD | 366,228 |
| ARKQ | GLEO | GALILEO ACQUISITION CORP | 325,800 |
| ARKQ | NVDA | NVIDIA CORP | 4,050 |
| ARKQ | RAVN | RAVEN INDUSTRIES INC | 12,814 |
| ARKQ | TCEHY | TENCENT HOLDINGS LTD | 36,315 |
| ARKW | TCEHY | TENCENT HOLDINGS LTD | 46,793 |
| ARKW | PSTG | PURE STORAGE INC | 187,131 |
| ARKW | NET | CLOUDFLARE INC | 69,294 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
